Therapeutic eradication choices in Helicobacter pylori infection in children.

IF 4.2 3区 医学
Therapeutic Advances in Gastroenterology Pub Date : 2023-04-27 eCollection Date: 2023-01-01 DOI:10.1177/17562848231170052
Marco Manfredi, Giancarlo Gargano, Pierpacifico Gismondi, Bernardino Ferrari, Silvia Iuliano
{"title":"Therapeutic eradication choices in <i>Helicobacter pylori</i> infection in children.","authors":"Marco Manfredi, Giancarlo Gargano, Pierpacifico Gismondi, Bernardino Ferrari, Silvia Iuliano","doi":"10.1177/17562848231170052","DOIUrl":null,"url":null,"abstract":"<p><p>Current recommendations on <i>Helicobacter pylori</i> (<i>H. pylori</i>) eradication in children differ from adults. In <i>H. pylori</i>-infected adults, the eradication is always recommended because of the risk to develop gastrointestinal and non-gastrointestinal associated diseases. Instead, before treating infected children, we should consider all the possible causes and not merely focus on <i>H. pylori</i> infection. Indeed, pediatric international guidelines do not recommend the <i>test and treat strategy</i> in children. Therefore, gastroscopy with antimicrobial susceptibility testing by culture on gastric biopsies should be performed before starting the eradication therapy in children to better evaluate all the possible causes of the symptomatology and to increase the eradication rate. Whether antibiotic susceptibility testing is not available, gastroscopy is anyway recommended to better set any possible cause of symptoms and not simply focus on the presence of <i>H. pylori</i>. In children the lower antibiotics availability compared to adults forces to treat based on antimicrobial susceptibility testing to minimize the unsuccessful rates. The main antibiotics used in children are amoxicillin, clarithromycin, and metronidazole in various combinations. In empirical treatment, triple therapy for 14 days based either on local antimicrobial susceptibility or on personal antibiotic history is generally recommended. Triple therapy with high dose of amoxicillin is a valid alternative choice, either in double resistance or in second-line treatment. Moving from therapeutic regimens used in adults, we could also select quadruple therapy with or without bismuth salts. However, all the treatment regimens often entail unpleasant side effects and lower compliance in children. In this review, the alternative and not yet commonly used therapeutic choices in children were also analyzed.</p>","PeriodicalId":23022,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"16 ","pages":"17562848231170052"},"PeriodicalIF":4.2000,"publicationDate":"2023-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d9/a0/10.1177_17562848231170052.PMC10141265.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562848231170052","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Current recommendations on Helicobacter pylori (H. pylori) eradication in children differ from adults. In H. pylori-infected adults, the eradication is always recommended because of the risk to develop gastrointestinal and non-gastrointestinal associated diseases. Instead, before treating infected children, we should consider all the possible causes and not merely focus on H. pylori infection. Indeed, pediatric international guidelines do not recommend the test and treat strategy in children. Therefore, gastroscopy with antimicrobial susceptibility testing by culture on gastric biopsies should be performed before starting the eradication therapy in children to better evaluate all the possible causes of the symptomatology and to increase the eradication rate. Whether antibiotic susceptibility testing is not available, gastroscopy is anyway recommended to better set any possible cause of symptoms and not simply focus on the presence of H. pylori. In children the lower antibiotics availability compared to adults forces to treat based on antimicrobial susceptibility testing to minimize the unsuccessful rates. The main antibiotics used in children are amoxicillin, clarithromycin, and metronidazole in various combinations. In empirical treatment, triple therapy for 14 days based either on local antimicrobial susceptibility or on personal antibiotic history is generally recommended. Triple therapy with high dose of amoxicillin is a valid alternative choice, either in double resistance or in second-line treatment. Moving from therapeutic regimens used in adults, we could also select quadruple therapy with or without bismuth salts. However, all the treatment regimens often entail unpleasant side effects and lower compliance in children. In this review, the alternative and not yet commonly used therapeutic choices in children were also analyzed.

Abstract Image

Abstract Image

Abstract Image

儿童幽门螺旋杆菌感染的根除治疗选择。
目前关于儿童根除幽门螺旋杆菌(H. pylori)的建议与成人不同。对于感染幽门螺杆菌的成人,由于可能会患上胃肠道和非胃肠道相关疾病,因此总是建议根除幽门螺杆菌。相反,在治疗受感染的儿童之前,我们应该考虑所有可能的原因,而不仅仅是幽门螺杆菌感染。事实上,儿科国际指南并不建议对儿童采取检测和治疗策略。因此,在开始对儿童进行根除治疗之前,应进行胃镜检查,并通过培养对胃活检组织进行抗菌药物药敏试验,以更好地评估导致症状的所有可能原因,提高根除率。如果无法进行抗生素药敏试验,则建议进行胃镜检查,以更好地确定引起症状的可能原因,而不仅仅是幽门螺杆菌的存在。与成人相比,儿童使用抗生素的机会较少,因此必须根据抗菌素药敏试验进行治疗,以尽量减少治疗失败率。儿童使用的主要抗生素是阿莫西林、克拉霉素和甲硝唑的不同组合。在经验性治疗中,一般建议根据当地抗菌药敏感性或个人抗生素使用史进行为期 14 天的三联疗法。在双重耐药或二线治疗中,使用大剂量阿莫西林的三联疗法是一种有效的替代选择。根据成人使用的治疗方案,我们还可以选择含或不含铋盐的四联疗法。然而,所有这些治疗方案通常都会带来令人不快的副作用,而且儿童的依从性较低。在这篇综述中,我们还分析了在儿童中尚未常用的替代疗法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Therapeutic Advances in Gastroenterology
Therapeutic Advances in Gastroenterology Medicine-Gastroenterology
自引率
2.40%
发文量
103
期刊介绍: Therapeutic Advances in Gastroenterology is an open access journal which delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of gastrointestinal and hepatic disorders. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in gastroenterology and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area. The editors welcome original research articles across all areas of gastroenterology and hepatology. The journal publishes original research articles and review articles primarily. Original research manuscripts may include laboratory, animal or human/clinical studies – all phases. Letters to the Editor and Case Reports will also be considered.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信